Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04994522 · ClinicalTrials.gov registry record · Phase 1
A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04994522 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 14 participants.
The verdict
NCT04994522, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of belzutifan (MK-6482) following a single oral 120 mg dose in participants with end stage renal disease (ESRD) before and after hemodialysis (HD) to each other and also to that of healthy matched control participants. This study will also evaluate the safety and tolerability of a single oral 120 mg dose of belzutifan in participants with ESRD and the extent of belzutifan removed by HD.
Interventions
- DRUG Belzutifan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-07-12 |
| Est. Completion | 2024-04-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04994522
The ClinicalTrials.gov registry entry for NCT04994522 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belzutifan is the first listed.
NCT04994522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04994522 about?
NCT04994522 is a clinical study titled "A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)". The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of belzutifan (MK-6482) following a single oral 120 mg dose in participants with end stage renal disease (ESRD) before and after hemodialysis (HD) to each other and also to that of healthy matched control participants. ...
What is the current status of trial NCT04994522?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-07-12. Estimated completion is 2024-04-11.
What interventions are being tested in trial NCT04994522?
The interventions under investigation include: Belzutifan (DRUG).
Who is sponsoring clinical trial NCT04994522?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.